Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.

PURPOSE:The receptors for hepatocyte and vascular endothelial cell growth factors (MET and VEGFR2, respectively) are critical oncogenic mediators in gastric adenocarcinoma. The purpose is to examine the safety and efficacy of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, a...

Full description

Bibliographic Details
Main Authors: Manish A Shah, Zev A Wainberg, Daniel V T Catenacci, Howard S Hochster, James Ford, Pamela Kunz, Fa-Chyi Lee, Howard Kallender, Fabiola Cecchi, Daniel C Rabe, Harold Keer, Anne-Marie Martin, Yuan Liu, Robert Gagnon, Peter Bonate, Li Liu, Tona Gilmer, Donald P Bottaro
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23516391/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23516391/?tool=EBI

Similar Items